DRDO-developed technology behind critical drug approved by DCGI for radiological and nuclear emergencies

DRDO-developed technology behind critical drug approved by DCGI for radiological and nuclear emergencies

• The manufacturing and marketing licenses for the commercial use of Prussian blue insoluble formulations have been granted to Scott-Edil Pharmacia Limited, Himachal Pradesh and SkanttrLifescience, Gujarat by Drugs Controller General of India.

• It is one of the critical medicines listed by the World Health Organisation for radiological and nuclear emergencies. Defence Ministry said, the drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG.

• The formulations are used for decontamination of Cesium and Thallium and its Active Pharmaceutical Ingredient. The drug has been developed by the industry based on the technology of Institute of Nuclear Medicine and Allied Sciences, Delhi, a laboratory of Defence Research and Development Organisation (DRDO).

February Weekly Current Affairs (Important Dates) Bitbank: On which day the World Unani Day is marked annually?

                         >> Download Current Affairs PDFs Here

                              Download Sakshi Education Mobile APP

Published date : 16 Mar 2023 06:04PM